Table 2.
Sites of Treatment Failure According to Clinical Features of Cervical Cancer and Treatment
| Features | Total | Treatment Failure | |||
|---|---|---|---|---|---|
| No | Yes | ||||
| Persistence | Progression | Recurrence | |||
| Histology | |||||
| SCC | 198 | 139 (70.2) | 21 (10.6) | 15 (7.6) | 23 (11.6) |
| ACA/ AS | 61 | 35 (57.4) | 10 (16.4) | 1 (1.6) | 15 (24.6) |
| Age group | |||||
| ≤ 40 years | 43 | 29 (67.4) | 4 (9.3) | 2 (4.7) | 8 (18.6) |
| > 40 years | 216 | 145 (67.1) | 27 (12.5) | 14 (6.5) | 30 (13.9) |
| FIGO 2018 stage | |||||
| IIB | 131 | 101 (77.1) | 11 (8.4) | 7 (5.3) | 12 (9.2) |
| IIIA | 3 | 1 (33.3) | - | 1 (33.3) | 1 (33.3) |
| IIIB | 60 | 40 (66.7) | 8 (13.3) | 2 (3.3) | 10 (16.7) |
| IIIC1r | 62 | 31 (50) | 11 (17.7) | 5 (8.1) | 15 (24.2) |
| IVA | 3 | 1 (33.3) | 1 (33.3) | 1 (33.3) | - |
| Tumor size | |||||
| ≤ 4 cm. | 96 | 73 (76) | 7 (7.3) | 6 (6.3) | 10 (10.4) |
| > 4 cm. | 163 | 101 (62) | 24 (14.7) | 10 (6.1) | 28 (17.2) |
| Total radiation dose | |||||
| <85 Gy | 23 | 9 (39.1) | 10 (43.5) | 3 (13) | 1 (4.3) |
| ≥85 Gy | 236 | 165 (69.9) | 21 (8.9) | 13 (5.5) | 37 (15.7) |
| Total treatment times | |||||
| ≤ 56 days | 123 | 84 (68.3) | 16 (13) | 6 (4.9) | 17 (13.8) |
| >56 Days | 136 | 90 (66.2) | 15 (11) | 10 (7.4) | 21 (15.4) |
| Cisplatin cycle | |||||
| <5 cycles | 67 | 43 (64.2) | 16 (23.9) | 4 (6) | 4 (6) |
| ≥ 5 cycles | 192 | 131 (68.2) | 15 (7.8) | 12 (6.3) | 34 (17.7) |
| Cisplatin total dose | |||||
| <200 mg | 52 | 30 (57.7) | 15 (28.8) | 3 (5.8) | 4 (7.7) |
| ≥200 mg | 207 | 144 (69.6) | 16 (7.7) | 13 (6.3) | 34 (16.4) |